Sava raises £14m Series A led by Balderton and Pentland Venture to pioneer real-time biosensing for diabetes care

Sava develops a wearable biosensing platform that monitors glucose and other biomarkers in real time, using a pain-free microsensor designed to expand access to continuous health monitoring.